Drug research and development company Curemark has won a new patent for its proprietary technology CM-1212 to treat drug and alcohol addiction.
The new patent is entitled 'Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same.'
Curemark founder and CEO Dr Joan Fallon said physiological symptoms of drug and alcohol addiction involve impairments in protein breakdown caused by a lack of key enzymes.
"These symptoms have not been identified nor addressed in the current treatment and management of addiction," Fallon added.
"We believe Curemark's findings on the effects of impairments in protein breakdown on the brain will provide new understanding of the complex factors of addiction."
Presently, Curemark is developing a treatment for autism, CM-AT, which has US Food and Drug Administration fast track designation.
